Home
OSTX
OSTX News

Latest OS THERAPIES INCORPORATED (OSTX) News on December 18, 2024

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

a month ago

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies to Present at The Spartan Capital Investor Conference

Business Wire

a month ago

OS Therapies to Present at The Spartan Capital Investor Conference

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

Business Wire

2 months ago

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Business Wire

2 months ago

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

OS Therapies to Present at the LD Micro Main Event XVII

Business Wire

2 months ago

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Business Wire

2 months ago

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Business Wire

3 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Business Wire

3 months ago

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

ACCESSWIRE

3 months ago

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Business Wire

3 months ago

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Business Wire

4 months ago

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

Business Wire

4 months ago

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

OS Therapies Clarifies CUSIP of Common Stock

Business Wire

4 months ago

OS Therapies Clarifies CUSIP of Common Stock

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Business Wire

4 months ago

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

OS Therapies Reports Second Quarter 2024 Financial Results

ACCESSWIRE

4 months ago

OS Therapies Reports Second Quarter 2024 Financial Results

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

4 months ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

ACCESSWIRE

4 months ago

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

Share on Social Networks: